Compareing effects of duloxetinein and Placebo on depression, withdrawal symptoms, craving

Phase 2

• Conditions: Methamphetamine dependency.; Hallucinogen abuse

• Registration Number: IRCT20160717028967N7
• Lead Sponsor: Kermanshah University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 16 July 2018

Recruitment & Eligibility

• Status: Pending
• Sex: Male
• Target Recruitment: 66

Inclusion Criteria

Gender Male
Methamphetamine dependence diagnoses accordingly Diagnostic and Statistical Manual of Mental Disorders fifth edition
The dominant use of methamphetamine for at least 6 months
lack of serious psychiatric disorders

Exclusion Criteria

subjects who met opiates dependence
non compliance or not willing for continuing the study
sever and unbearable drug side effect even after reducing the dose.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Depression. Timepoint: before intervention- 4 weeks later- 8 weeks later. Method of measurement: Depression Inventory.;Withdrawal symptoms. Timepoint: before intervention- 4 weeks later- 8 weeks later. Method of measurement: Inventory withdrawal symptoms.;Craving. Timepoint: before intervention- 4 weeks later- 8 weeks later. Method of measurement: Craving Questionnaire.